Table 1.
Baseline patient characteristics for all randomized, genotyped patients, by treatment allocation and by treatment discontinuation.
| All enrolled, genotyped patients (n=467) | Randomized to letrozole (n=232) | Randomized to exemestane (n=235) | Discontinued AI because of symptoms (n=152) | Continued AI (n=280) | |
|---|---|---|---|---|---|
| Median age, yrs (range) | 59 (35–89) | 59 (38–89) | 59 (35–83) | 57.5 (37–83) | 60 (35–84) |
| Race | |||||
| - White | 413 (88.4%) | 203 (87.5%) | 210 (89.4%) | 138 (91.5%) | 247 (88.2%) |
| - Black | 42 (9.0%) | 24 (10.3%) | 18 (7.7%) | 12 (7.4%) | 25 (8.9%) |
| - Other | 12 (2.6%) | 5 (2.2%) | 7 (3.0%) | 2 (1.2%) | 8 (2.9%) |
| Weight, kg (SD) | 79.5 (17.6) | 79.4 (17.9) | 79.7 (17.2) | 78.5 (16.3) | 80.7 (18.0) |
| BMI (SD) | 30.0 (6.4) | 30.1 (6.7) | 29.9 (6.2) | 29.6 (6.1) | 30.4 (6.5) |
| Prior tamoxifen | 169 (36.2%) | 85 (36.6%) | 84 (35.7%) | 59 (38.9%) | 96 (34.3%) |
| Prior HRT | 227 (48.6%) | 105 (45.3%) | 122 (51.9%) | 75 (48.8%) | 145 (51.8%) |
| Prior chemotherapy | 212 (45.4%) | 104 (44.8%) | 108 (46.0%) | 68 (44.4%) | 124 (44.3%) |
| Prior taxane | 153 (32.8%) | 77 (33.2%) | 76 (32.3%) | 55 (35.8%) | 85 (30.4%) |
| Mean time since chemotherapy, yrs (SD) | 1.7 (1.9) | 1.6 (1.8) | 1.8 (1.9) | 1.6 (1.7) | 1.7 (2.0) |
| Assigned AI | |||||
| - Letrozole | 232 (49.7%) | 232 | 0 | 68 (44.7%) | 151 (53.9%) |
| - Exemestane | 235 (50.3%) | 0 | 235 | 84 (55.3%) | 129 (46.1%) |
AI=aromatase inhibitor; HRT=hormone replacement therapy; Kg=kilograms; N=number; SD =Standard deviation; yrs=years